Important Safety Considerations

Leukine^® (sargramostim) is contraindicated in patients with excessive leukemic myeloid blasts in bone marrow or peripheral blood (≥ 10%), in patients with known hypersensitivity to GM-CSF, yeast derived products or any component of Leukine, and for concomitant use with chemotherapy and radiotherapy.
Click here for additional Important Safety Information.
Click here for Indications.

Reimbursement

Sanofi US provides access to reimbursement consultants through the Leukine^® Direct reimbursement support line — 1-888-4RX-Leukine (888.479.5385) (8 AM to 6 PM ET, Monday through Friday). The Leukine Direct consultants can help:

Provide answers to reimbursement and coverage policy questions
Research patient-specific insurance coverage
Assist with claims preparation
Assist in identifying appropriate claims appeal strategies
Identify available payment sources for uninsured or underinsured patients

Reimbursement Support Line

Sanofi US offers product support services to help ensure patient and physician access to Leukine, including product-related reimbursement questions. Reimbursement consultants can be reached at the Leukine^® Direct reimbursement support line: 1-888-4RX-Leukine (888.479.5385) (8 AM to 6 PM ET, Monday through Friday).

Services Overview
The Reimbursement Support Line team has experience across all payer types, including Medicare. The team closely monitors policy changes, such as recent Medicare reform, to provide accurate and timely information. Questions answered by the team are wide-ranging, but typically can be classified into one of the following groups:

Benefit Verification: identifies patient-specific product coverage guidelines; can include identification of potential diagnosis restrictions and patient cost-sharing details
Prior-Authorization Assistance: consultants can act as a liaison between payer and provider to determine the prior-authorization process and requirements; can assist the provider in the creation of payer-requested information, such as a letter of medical necessity
Patient Assistance: a program Sanofi US offers that provides treatment to uninsured patients who meet program criteria

Reimbursement Assistance

Top Reasons Claims Are Denied
According to the Medical Group Management Association (MGMA), the 5 most common reasons for claim denial are:

Diagnosis is not coded to the highest level of specificity
Missing patient subscriber or ID number
Patient name and/or address doesn't match insurer's records
Missing physician information or ID number
Claim information is illegible or improperly entered

Tips for Appealing a Denied Claim
These simple steps can get your claim back on track:

Review your claim and be sure all the required fields are complete and correctly coded
Carefully read the explanation of benefits to understand exactly why the claim was denied
Submit to the payer a formal letter of appeal contesting the denial
Contact the payer's office if a response is not received in a timely manner
Utilize the LEUKINE Direct reimbursement support line

Leukine Resources

Resources

Indication

Leukine^® (sargramostim) is used to help increase the number and function of white blood cells after bone marrow transplantation, in cases of bone marrow transplantation failure or engraftment delay, before and after peripheral blood stem cell transplantation, and following induction chemotherapy in older patients with acute myelogenous leukemia. Your doctor may also choose to treat other conditions with Leukine.

Important Safety Information for Leukine^® (sargramostim)

You should not use Leukine if you have high levels of abnormal white blood cells, called leukemic blasts, in the bone marrow or blood. You should not use Leukine® if you have had an allergic reaction to GM-CSF, other products made from yeast, or any ingredient used to make Leukine. If you are also receiving chemotherapy or radiation therapy, do not take your Leukine in the period 24 hours before through 24 hours after the administration of your chemotherapy or radiation therapy.
A generalized allergy is an uncommon but potentially serious reaction to Leukine. This may include askin rash over your entire body, hives, trouble breathing, a fast pulse, sweating, and feeling faint. In severe cases a generalized allergy may be life-threatening. If you think you are having a generalized allergy to Leukine, stop taking Leukine and notify your doctor immediately.
Liquid solutions containing benzyl alcohol, including Leukine liquid or lyophilized Leukine reconstituted with Bacteriostatic Water For Injection, USP should not be administered to newborns.
Leukine should be used with caution, and your doctor should monitor you if you have preexisting fluid buildup, heart or lung conditions, or kidney or liver disease.
Some patients taking Leukine may experience unwanted side effects, most of which are mild to moderate and not serious. Some of the more common side effects include bone pain, feeling like you have the flu, feeling tired or weak, muscle aches, diarrhea, stomach upset, weight loss, or loss of appetite. You may also get a low-grade fever (less than 100.5°F or 38°C) about 1 to 4 hours after an injection, or you may have swelling, redness, and/or discomfort where Leukine was injected.
Some side effects or symptoms may be serious. These include developing a high fever (over 100.5°F or 38°C), signs of infection including chills, sore throat, or congestion (such as stuffy nose), having trouble breathing, wheezing, or fainting, or developing extensive skin rash, hives, or other signs of an allergic reaction, experiencing sudden weight gain or other signs of fluid buildup, such as swollen legs or feet, having chest pain, chest discomfort, or a rapid or irregular pulse. These may be due to Leukine, your illness, or other treatments that you may have received. Many of these side effects can be reduced or eliminated. These or other side effects you may be concerned about should be reported promptly to your doctor, nurse, or pharmacist.
Your doctor will monitor your white blood cell and platelet counts with blood tests during Leukine treatment. If your white blood cell or platelet counts rise above certain levels, your doctor may stop your Leukine treatment, or may reduce the dose. If your doctor detects progression of your disease, he/she may stop your Leukine therapy.
Drugs that can increase WBCs, such as lithium and corticosteroids, should be used with caution while receiving Leukine Interactions between Leukine and other drugs have not been fully evaluated.

Please see full Prescribing Information.